Imatinib for small cell lung cancer, aiming for a target in vivo.

Abstract

There are an estimated 25,000 patients who develop small cell lung cancer per year in the United States. The currently available therapy is inadequate because >95% of patients die from their small cell lung cancer [(1][1] [, 2)][2] . The work with conventional chemotherapy has not dramatically